Confronto
Semaglutid vs. Survodutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
910463-68-2
2179963-22-7
Peso molecolare
4113.6 g/mol
4727 g/mol
Emivita
165 h
168 h
Sequenza
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linkermodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMeccanismo d'azione
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
3
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
5
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Semaglutid and Survodutide?
- Semaglutid is classified as "Metabolico", while Survodutide is classified as "Metabolico". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Semaglutid or Survodutide?
- The highest available evidence level is "RCT sull'uomo" for Semaglutid and "RCT sull'uomo" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Semaglutid and Survodutide in Germany and the United States?
- Germania: Semaglutid — Su prescrizione, Survodutide — Non approvato. Stati Uniti: Semaglutid — Su prescrizione, Survodutide — Non approvato. These are factual summaries with source and review date on the individual pages.